These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6702280)

  • 1. [Thrombolysis using urokinase in acute phlebothrombosis].
    Minar E; Ehringer H; Marosi L; Sommer G; Deutsch E
    Vasa; 1984; 13(1):41-6. PubMed ID: 6702280
    [No Abstract]   [Full Text] [Related]  

  • 2. Experimental and clinical studies on thrombolytic therapy with urokinase.
    Shiba T; Igarashi M; Takeuchi S; Awazu S; Asada T
    Nihon Ketsueki Gakkai Zasshi; 1978 Aug; 41(4):771-81. PubMed ID: 82362
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biochemistry and clinical significance of urokinase].
    Andrassy K; Ritz E
    Dtsch Med Wochenschr; 1978 Jun; 103(24):1011, 1015-20. PubMed ID: 350536
    [No Abstract]   [Full Text] [Related]  

  • 4. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
    Maksimenko AV
    Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thrombolysis with Urokinase after anaphylaxis caused by streptokinase treatment (author's transl)].
    Walter B; Tamm D
    Med Klin; 1979 Feb; 74(7):239-41. PubMed ID: 763216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thrombolytic treatment of deep leg and pelvic vein thromboses].
    Breddin HK; Krzywanek HJ
    Internist (Berl); 1982 Jul; 23(7):410-6. PubMed ID: 7050003
    [No Abstract]   [Full Text] [Related]  

  • 7. Biochemical and clinical aspects of thrombolysis.
    Verstraete M
    Semin Hematol; 1978 Jan; 15(1):35-54. PubMed ID: 341327
    [No Abstract]   [Full Text] [Related]  

  • 8. [Late lysis of venous thromboses].
    Tilsner V
    Vasa; 1974; 3(4):458-60. PubMed ID: 4440227
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experience with urokinase in chronic arterial occlusive disease and long-standing phlebothrombosis].
    Trübestein G; Brecht T; Brecht G; Etzel F
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1948-50. PubMed ID: 1030145
    [No Abstract]   [Full Text] [Related]  

  • 10. [Late results following fibrinolysis therapy of venous thromboses].
    Breddin HK
    Internist (Berl); 1984 Feb; 25(2):102-7. PubMed ID: 6368451
    [No Abstract]   [Full Text] [Related]  

  • 11. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
    Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
    Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fibrinolytic therapy. Indications and execution].
    Trübestein G
    Dtsch Med Wochenschr; 1985 Sep; 110(37):1417-9. PubMed ID: 4028995
    [No Abstract]   [Full Text] [Related]  

  • 13. [Arterial and venous thrombosis of the extremities].
    Urano T; Sakaguchi S; Kamiya T; Ishii K; Takada Y; Takada A
    Rinsho Ketsueki; 1984 Jul; 25(7):1036-42. PubMed ID: 6502955
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
    Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
    Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
    [No Abstract]   [Full Text] [Related]  

  • 15. Leukocyte-plasma interaction in fibrinolysis. A new dimension in the action of urokinase.
    Moroz LA; Sniderman AD; Marpole DG
    N Engl J Med; 1979 Nov; 301(20):1100-4. PubMed ID: 158709
    [No Abstract]   [Full Text] [Related]  

  • 16. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
    Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful fibrinolytic treatment with urokinase six weeks after leg and pelvic vein thrombosis (author's transl)].
    Trübestein G; Etzel F; Sobbe A
    Dtsch Med Wochenschr; 1974 Nov; 99(48):2457-9. PubMed ID: 4448142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.